Form 4: Charles River Labs Director Acquires Shares

Director James C. Foster of Charles River Laboratories International, Inc. reported the acquisition of 1,438 and 422 shares of common stock on May 8, 2026, at a price of $177.62 per share.

Summary

• Director James C. Foster acquired 1,438 shares of common stock on May 8, 2026, for $177.62 per share.
• An additional 422 shares of common stock were acquired by Director Foster on May 8, 2026, also at $177.62 per share.
• These acquisitions bring the total directly owned common stock to 281,553 shares.
• The filing also lists various indirect holdings of common stock, including those held in trusts and by a spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions without providing new financial performance data or strategic outlook.

Positives

• Director James C. Foster has increased his direct beneficial ownership of Charles River Laboratories International, Inc. common stock.
• The acquisition of 1,860 shares (1,438 + 422) indicates confidence or a planned transaction by a key insider.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are common in the life sciences and contract research organization (CRO) sector. These filings provide transparency into the holdings and transactions of key company personnel.

Stakeholder Impact

• Shareholders: The filing provides transparency into insider holdings, which can be a factor in investor sentiment, but does not directly impact share value without further context.

Key Dates

Keywords

Charles River Laboratories, CRL, Form 4, Insider Transaction, Director, Common Stock, Beneficial Ownership